Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-alpha production.
Clark MP, Laughlin SK, Laufersweiler MJ, Bookland RG, Brugel TA, Golebiowski A, Sabat MP, Townes JA, VanRens JC, Djung JF, Natchus MG, De B, Hsieh LC, Xu SC, Walter RL, Mekel MJ, Heitmeyer SA, Brown KK, Juergens K, Taiwo YO, Janusz MJ. Clark MP, et al. Among authors: laufersweiler mj. J Med Chem. 2004 May 20;47(11):2724-7. doi: 10.1021/jm049968m. J Med Chem. 2004. PMID: 15139749
The development of novel inhibitors of tumor necrosis factor-alpha (TNF-alpha) production based on substituted [5,5]-bicyclic pyrazolones.
Laufersweiler MJ, Brugel TA, Clark MP, Golebiowski A, Bookland RG, Laughlin SK, Sabat MP, Townes JA, VanRens JC, De B, Hsieh LC, Heitmeyer SA, Juergens K, Brown KK, Mekel MJ, Walter RL, Janusz MJ. Laufersweiler MJ, et al. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4267-72. doi: 10.1016/j.bmcl.2004.06.001. Bioorg Med Chem Lett. 2004. PMID: 15261284
The development of new bicyclic pyrazole-based cytokine synthesis inhibitors.
Townes JA, Golebiowski A, Clark MP, Laufersweiler MJ, Brugel TA, Sabat M, Bookland RG, Laughlin SK, VanRens JC, De B, Hsieh LC, Xu SC, Janusz MJ, Walter RL. Townes JA, et al. Among authors: laufersweiler mj. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4945-8. doi: 10.1016/j.bmcl.2004.07.024. Bioorg Med Chem Lett. 2004. PMID: 15341957
The development of monocyclic pyrazolone based cytokine synthesis inhibitors.
Golebiowski A, Townes JA, Laufersweiler MJ, Brugel TA, Clark MP, Clark CM, Djung JF, Laughlin SK, Sabat MP, Bookland RG, VanRens JC, De B, Hsieh LC, Janusz MJ, Walter RL, Webster ME, Mekel MJ. Golebiowski A, et al. Among authors: laufersweiler mj. Bioorg Med Chem Lett. 2005 May 2;15(9):2285-9. doi: 10.1016/j.bmcl.2005.03.007. Bioorg Med Chem Lett. 2005. PMID: 15837310
The development of new isoxazolone based inhibitors of tumor necrosis factor-alpha (TNF-alpha) production.
Laughlin SK, Clark MP, Djung JF, Golebiowski A, Brugel TA, Sabat M, Bookland RG, Laufersweiler MJ, VanRens JC, Townes JA, De B, Hsieh LC, Xu SC, Walter RL, Mekel MJ, Janusz MJ. Laughlin SK, et al. Among authors: laufersweiler mj. Bioorg Med Chem Lett. 2005 May 2;15(9):2399-403. doi: 10.1016/j.bmcl.2005.02.066. Bioorg Med Chem Lett. 2005. PMID: 15837333
Development of N-2,4-pyrimidine-N-phenyl-N'-alkyl ureas as orally active inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 2.
Maier JA, Brugel TA, Clark MP, Sabat M, Golebiowski A, Bookland RG, Laufersweiler MJ, Laughlin SK, Vanrens JC, De B, Hsieh LC, Brown KK, Juergens K, Walter RL, Janusz MJ. Maier JA, et al. Among authors: laufersweiler mj. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3514-8. doi: 10.1016/j.bmcl.2006.03.096. Epub 2006 Apr 24. Bioorg Med Chem Lett. 2006. PMID: 16632350
Development of N-2,4-pyrimidine-N-phenyl-N'-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 1.
Brugel TA, Maier JA, Clark MP, Sabat M, Golebiowski A, Bookland RG, Laufersweiler MJ, Laughlin SK, Vanrens JC, De B, Hsieh LC, Mekel MJ, Janusz MJ. Brugel TA, et al. Among authors: laufersweiler mj. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3510-3. doi: 10.1016/j.bmcl.2006.03.095. Epub 2006 May 2. Bioorg Med Chem Lett. 2006. PMID: 16632356
The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
Sabat M, Vanrens JC, Brugel TA, Maier J, Laufersweiler MJ, Golebiowski A, De B, Easwaran V, Hsieh LC, Rosegen J, Berberich S, Suchanek E, Janusz MJ. Sabat M, et al. Among authors: laufersweiler mj. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4257-61. doi: 10.1016/j.bmcl.2006.05.072. Epub 2006 Jun 6. Bioorg Med Chem Lett. 2006. PMID: 16757169
16 results